Simplified novel prognostic score for real-life older adults with multiple myelomaregistry-based analysis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA20021TN" target="_blank" >RIV/61988987:17110/19:A20021TN - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/19:00109477 RIV/00216208:11110/19:10398544 RIV/00216208:11150/19:10398544 RIV/61989592:15110/19:73589408 a 5 dalších

Výsledek na webu

<a href="https://link.springer.com/content/pdf/10.1007/s00277-018-3568-2.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s00277-018-3568-2.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00277-018-3568-2" target="_blank" >10.1007/s00277-018-3568-2</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Simplified novel prognostic score for real-life older adults with multiple myelomaregistry-based analysis

Popis výsledku v původním jazyce

The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65years with symptomatic myeloma were included. The four major parameters with impact on survival were identified: male gender, age>75, creatinine >152mol/L, and ECOG performance status 2-4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3-4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8-81.7) for good, 51.0 (44.1-57.8) for intermediate good, 32.2 (26.2-38.2) for intermediate poor, and 18.9 (15.1-22.7) for poor. The differences in OS were statistically significant (p&lt;0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09-1.84) for intermediate good, 2.58 (2.00-3.33) for intermediate poor, and 3.88 (2.94-5.10) for poor. Time to progression showed medians (months) 20.5 (17.4-62.4) for good, 19.3 (17.0-21.7) for intermediate good, 19.6 (16.2-23.0) for intermediate poor, and 13.0 (10.8-15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65years.

Název v anglickém jazyce

Simplified novel prognostic score for real-life older adults with multiple myelomaregistry-based analysis

Popis výsledku anglicky

The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65years with symptomatic myeloma were included. The four major parameters with impact on survival were identified: male gender, age>75, creatinine >152mol/L, and ECOG performance status 2-4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3-4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8-81.7) for good, 51.0 (44.1-57.8) for intermediate good, 32.2 (26.2-38.2) for intermediate poor, and 18.9 (15.1-22.7) for poor. The differences in OS were statistically significant (p&lt;0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09-1.84) for intermediate good, 2.58 (2.00-3.33) for intermediate poor, and 3.88 (2.94-5.10) for poor. Time to progression showed medians (months) 20.5 (17.4-62.4) for good, 19.3 (17.0-21.7) for intermediate good, 19.6 (16.2-23.0) for intermediate poor, and 13.0 (10.8-15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65years.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ANN HEMATOL

ISSN

0939-5555

e-ISSN

1432-0584

Svazek periodika

98

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

951-962

Kód UT WoS článku

000461545800016

EID výsledku v databázi Scopus

—